ArticleFrontiers in microbiology2026
Development and characterization of a monoclonal antibody against Pseudorabies virus glycoprotein B and its application in tracking viral infection.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pseudorabies virus (PRV) is a swine herpesvirus that causes severe economic losses in the global pig industry. Glycoprotein B (gB) is a highly conserved envelope glycoprotein of PRV and plays an essential role in viral entry, cell fusion, and antibody induction. Here, the extracellular domain of gB from PRV HeN1 strain was expressed in CHO cells and purified. After mouse immunization and hybridoma fusion, a gB-specific monoclonal antibody 1G4 was identified via ELISA and IFA. 1G4 presented high specificity, good reactivity and broad cross-recognition against multiple PRV strains. FITC-labeled 1G4, combined with a gD-targeted mAb, was applied to visualize PRV adsorption and internalization in HeLa cells by confocal microscopy at fixed time points. In conclusion, this novel gB mAb serves as a reliable reagent for PRV mechanism research and immunological detection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.